intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.
Company profile
Ticker
ITCI
Exchange
Website
CEO
Sharon Mates
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Oneida Resources Corp.
SEC CIK
Corporate docs
Subsidiaries
ITI, Inc. ...
IRS number
364742850
ITCI stock data
Latest filings (excl ownership)
8-K
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
16 Apr 24
424B5
Prospectus supplement for primary offering
16 Apr 24
S-3ASR
Automatic shelf registration
16 Apr 24
8-K
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
16 Apr 24
8-K
Other Events
1 Apr 24
8-K
Intra-cellular Therapies Announces Executive Appointments and Leadership Changes
19 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
22 Feb 24
8-K
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
Transcripts
ITCI
Earnings call transcript
2023 Q4
22 Feb 24
ITCI
Earnings call transcript
2023 Q3
2 Nov 23
ITCI
Earnings call transcript
2023 Q2
3 Aug 23
ITCI
Earnings call transcript
2023 Q1
4 May 23
ITCI
Earnings call transcript
2022 Q4
1 Mar 23
ITCI
Earnings call transcript
2022 Q3
3 Nov 22
ITCI
Earnings call transcript
2022 Q2
9 Aug 22
ITCI
Earnings call transcript
2022 Q1
10 May 22
ITCI
Earnings call transcript
2021 Q4
1 Mar 22
ITCI
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
4
NOSTRAND ROBERT L VAN
2 Apr 24
4
RORY B RIGGS
2 Apr 24
4
RORY B RIGGS
22 Mar 24
4
Sharon Mates
11 Mar 24
4
Lawrence J. Hineline
11 Mar 24
4
Michael Halstead
11 Mar 24
4
Mark Neumann
11 Mar 24
4
Suresh K. Durgam
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 101.15 mm | 101.15 mm | 101.15 mm | 101.15 mm | 101.15 mm | 101.15 mm |
Cash burn (monthly) | 14.29 mm | 3.00 mm | 9.90 mm | 14.39 mm | 8.42 mm | 13.44 mm |
Cash used (since last report) | 94.81 mm | 19.89 mm | 65.73 mm | 95.51 mm | 55.90 mm | 89.23 mm |
Cash remaining | 6.34 mm | 81.27 mm | 35.42 mm | 5.64 mm | 45.25 mm | 11.92 mm |
Runway (months of cash) | 0.4 | 27.1 | 3.6 | 0.4 | 5.4 | 0.9 |
Institutional ownership, Q3 2023
92.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 284 |
Opened positions | 40 |
Closed positions | 37 |
Increased positions | 121 |
Reduced positions | 84 |
13F shares | Current |
---|---|
Total value | 4.48 tn |
Total shares | 89.61 mm |
Total puts | 207.00 k |
Total calls | 201.00 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
FMR | 10.98 mm | $571.93 bn |
Vanguard | 8.54 mm | $444.83 bn |
BLK Blackrock | 7.51 mm | $391.45 bn |
Wasatch Advisors | 3.80 mm | $198.11 bn |
BBBOF BB Biotech | 3.54 mm | $112.52 mm |
BLVGF Bellevue | 3.17 mm | $165.14 bn |
Deep Track Capital | 2.60 mm | $135.43 bn |
STT State Street | 2.14 mm | $111.23 bn |
JPM JPMorgan Chase & Co. | 2.06 mm | $107.50 bn |
IVZ Invesco | 1.94 mm | $100.81 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 24 | Van Nostrand Robert L | Common Stock | Grant | Acquire A | No | No | 69.2 | 79 | 5.47 k | 9,690 |
31 Mar 24 | Riggs Rory B | Common Stock | Grant | Acquire A | No | No | 69.2 | 260 | 17.99 k | 99,495 |
20 Mar 24 | Riggs Rory B | Common Stock | Option exercise | Acquire M | No | No | 18.56 | 20,000 | 371.20 k | 99,235 |
20 Mar 24 | Riggs Rory B | Stock Option Common Stock | Option exercise | Dispose M | No | No | 18.56 | 20,000 | 371.20 k | 0 |
11 Mar 24 | Michael Halstead | Common Stock | Sell | Dispose S | No | Yes | 66.7 | 1,238 | 82.57 k | 0 |
11 Mar 24 | Michael Halstead | Common Stock | Sell | Dispose S | No | Yes | 65.82 | 6,107 | 401.96 k | 1,238 |
11 Mar 24 | Mark Neumann | Common Stock | Sell | Dispose S | No | Yes | 66.86 | 1,313 | 87.79 k | 29,700 |
11 Mar 24 | Mark Neumann | Common Stock | Sell | Dispose S | No | Yes | 65.92 | 1,729 | 113.98 k | 31,013 |
11 Mar 24 | Mark Neumann | Common Stock | Sell | Dispose S | No | Yes | 65.11 | 4,303 | 280.17 k | 32,742 |
10 Mar 24 | Michael Halstead | Common Stock | Option exercise | Acquire M | No | No | 0 | 7,345 | 0.00 | 7,345 |
News
Reported Earlier, Intra-Cellular Therapies Prices Public Offering Of 6,849,316 Common Shares At $73/Share
18 Apr 24
Goldman Sachs Maintains Neutral on Intra-Cellular Therapies, Raises Price Target to $77
17 Apr 24
B of A Securities Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $91
17 Apr 24
Baird Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $103
17 Apr 24
TD Cowen Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $90
17 Apr 24
Press releases
Intra-Cellular Therapies Prices Public Offering of Common Stock
17 Apr 24
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
16 Apr 24
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
16 Apr 24
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
19 Mar 24
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
6 Mar 24